Sarasin & Partners LLP Sells 49,029 Shares of Merck & Co., Inc. $MRK

Sarasin & Partners LLP lowered its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 6.2% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 736,662 shares of the company’s stock after selling 49,029 shares during the quarter. Sarasin & Partners LLP’s holdings in Merck & Co., Inc. were worth $94,661,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in MRK. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at about $25,000. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth about $26,000. Abound Financial LLC purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $26,000. IFC & Insurance Marketing Inc. purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $31,000. Finally, High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Get Merck & Co. Inc. alerts:

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst price-target increase: Guggenheim raised its Merck price target from $145 to $146 and maintained a Buy rating, implying meaningful upside from the referenced share price. This reinforces positive Wall Street sentiment. Benzinga
• Positive Sentiment: Keytruda gains another approval: Health Canada approved Keytruda with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer, expanding the drug’s use and potentially supporting sales before its major patent expirations. Health Canada approves Keytruda treatment
• Positive Sentiment: Pipeline and post-Keytruda strategy: Merck’s second-quarter commentary highlighted new product launches, pipeline progress and efforts to diversify into areas including vaccines, infectious diseases, hematology, cardiopulmonary disease and obesity. The company also raised its 2026 sales outlook, improving confidence in near-term execution. MRK Q2 earnings call
• Neutral Sentiment: Dividend comparison: Merck’s latest results have renewed debate over whether it offers a better income opportunity than Pfizer. The discussion may attract dividend-focused investors, but it does not represent a new company-specific catalyst. Pfizer or Merck dividend comparison
• Negative Sentiment: Keytruda patent risk remains central: Keytruda is approaching a significant patent cliff beginning in 2028. Merck is accelerating acquisitions and partnerships to offset the eventual revenue decline, but those investments can pressure earnings and increase execution risk. Merck is racing beyond Keytruda
• Negative Sentiment: Mixed pipeline development: Merck discontinued tulisokibart development in systemic sclerosis-associated interstitial lung disease, although the drug continues to be evaluated in other indications. The setback highlights clinical-development risk as Merck builds its post-Keytruda portfolio. MSD anti-TL1A trial update

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of recent analyst reports. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Citigroup began coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. BMO Capital Markets lifted their price target on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Barclays lifted their price target on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Finally, UBS Group upped their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Thirteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average target price of $134.56.

Get Our Latest Research Report on MRK

Merck & Co., Inc. Stock Down 0.0%

MRK stock opened at $128.27 on Friday. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.05. The business’s 50 day moving average price is $123.78 and its two-hundred day moving average price is $119.04. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company has a market capitalization of $316.81 billion, a price-to-earnings ratio of 102.62, a price-to-earnings-growth ratio of 5.14 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The business’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 2.72 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Featured Articles

• Five stocks we like better than Merck & Co., Inc.
• Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
• 4 Oil and Gas ETF Plays as Prices Stay Sky-High
• What Tesla Stands to Lose If It Walks Away From China
• Disney Sets Up for a Magical Year in 2027

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.